Inventory of Guidelines
ISLH is committed to ensuring an up to date inventory of guidelines that support the Hematology Laboratory community. To this end, below are additional guidelines.
Pre-analytical |
|||
Optimal Testing: AACC’s Guide to Lab Test Utilization |
AACC |
2020 |
|
Guidelines on the laboratory aspects of assays used in haemostasis and thrombosis |
BSH |
2020 |
|
Strategies for eliciting and synthesizing evidence for guidelines in rare diseases |
BMC |
2019 |
|
Reversal of direct oral anticoagulants: Guidance from the Anticoagulation Forum |
Anticoagulation Forum |
2019 |
|
Croatian Society of Medical Biochemistry and Laboratory Medicine: National recommendations for blood collection, processing, performance and reporting of results for coagulation screening assays prothrombin time, activated partial thromboplastin time, thrombin time, fibrinogen and D-dimer. |
Croatian Society of Medical Biochemistry and Laboratory Medicine |
2019 |
|
Joint EFLM-COLABIOCLI Recommendation for venous blood sampling |
EFLM-COLABIOCLI |
2018 |
|
Hematopathology |
|||
Nucleic acid amplification assays for molecular hematopathology: Approved Guideline – second edition |
CLSI |
2012 |
|
Coagulation |
|||
Recommendations for clinical laboratory testing of activated protein C resistance; communication from the SSC of the ISTH |
ISTH / SSC |
2019 |
|
Internal quality control practices in coagulation laboratories: recommendations based on a patterns-of-practice survey |
IQMH |
2015 |
Diagnosis of inherited platelet function disorders: guidance from the SSC of the ISTH |
ISTH |
2015 |
|
Testing for antiphospholipid antibodies with solid phase assays: guidance from the SSC of the ISTH |
ISTH |
2014 |
|
Validation of hemostasis and coagulation assays: recommendations and guidelines |
Independent authors (STH) |
2014 |
|
The diagnosis and management of von Willebrand disease: a United Kingdom Haemophilia Centre Doctors Organization guideline approved by the British Committee for Standards in Haematology |
UKHCDO / BCSH |
2014 |
|
European evidence-based recommendations for diagnosis and treatment of paediatric antiphospholipid syndrome: the SHARE initiative |
NIH |
2017 |
|
Activated Partial Thromboplastin Time Monitoring of Unfractionated Heparin Therapy: Issues and Recommendations |
NIH |
2017 |
|
Position Paper on laboratory testing for patients on direct oral anticoagulants. A Consensus Document from the SISET, FCSA, SIBioC and SIPMeL |
Blood Transfusion |
2017 |
|
International Council for Standardization in Haematology (ICSH) Recommendations for Laboratory Measurement of Direct Oral Anticoagulants |
ICSH |
2018 |
|
Laboratory criteria for antiphospholipid syndrome: communication from the SSC of the ISTH |
ISTH SSC |
2018 |
|
Lupus anticoagulant detection in anticoagulated patients. Guidance from the Scientific and Standardization Committee for lupus anticoagulant/antiphospholipid antibodies of the International Society on Thrombosis and Haemostasis |
ISTH SSC |
2020 |
|
Guidance from the Scientific and Standardization Committee for lupus anticoagulant/antiphospholipid antibodies of the International Society on Thrombosis and Haemostasis
|
ISTH SSC |
2020 |
|
Update of the guidelines for lupus anticoagulant detection and interpretation |
ISTH SSC |
2020 |
|
Recommendations for clinical laboratory testing for protein C deficiency, for the subcommittee on plasma coagulation inhibitors of the ISTH
|
ISTH SSC |
2020 |
|
Recommendations for clinical laboratory testing for protein S deficiency: Communication from the SSC committee plasma coagulation inhibitors of the ISTH | ISTH SSC |
2021 |
|
Hemoglobinopathies and other red cell disorders |
|||
ICSH recommendations for assessing automated high-performance liquid chromatography and capillary electrophoresis equipment for the quantitation of HbA2 |
ICSH |
2015 |
|
ICSH guidelines for the laboratory diagnosis of nonimmune hereditary red cell membrane disorders
Supporting information |
ICSH |
2015 |
|
ICSH recommendations for identification, diagnostic value, and quantitation of schistocytes |
ICSH |
2011 |
ICSH recommendations for identification, diagnostic value, and quantitation of schistocytes |
ICSH |
2011 |
Cellular analysis, including peripheral blood, bone marrow and body fluid analysis |
|||
The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. | WHO |
2016 |
|
ICSH recommendations for the standardization of nomenclature and grading of peripheral blood cell morphological features Supporting information |
ICSH |
2015 |
|
ICSH guidelines for the standardization of bone marrow immunohistochemistry |
ICSH |
2015 |
|
ICSH guidelines for the evaluation of blood cell analyzers including those used for differential leucocyte and reticulocyte counting |
ICSH |
2014 |
|
ICSH guidelines for the verification and performance of automated cell counters for body fluids |
ICSH |
2014 |
|
Initial Diagnostic Workup of Acute Leukemia: Guideline From the College of American Pathologists and the American Society of Hematology |
CAP |
2016 |
|
Flow Cytometry |
|
||
Immunophenotyping of acute leukemia and lymphoproliferative disorders: a consensus proposal of the European LeukemiaNet Work package 10 |
ESCCA |
2011 |
|
Minimal Residual Disease and Childhood Leukemia: Standard of Care Recommendations From the Pediatric Oncology Group of Ontario MRD Working Group |
PBC |
2016 |
|
ICCS/ESCCA consensus guidelines to detect GPI-deficient cells in paroxysmal nocturnal hemoglobinuria (PNH) and related disorders |
ICCS/ESCCA |
2018 |
The following guidelines are not restricted to laboratory testing:
A British Society for Haematology Guideline on the diagnosis and management of chronic myeloid leukaemia |
BSH |
2020 |
|
2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS) |
ECS |
2020 |
|
Standardizing Care to Manage Bleeding Disorders in Adolescents with Heavy Menses—A Joint Project from the ISTH Pediatric/Neonatal and Women's Health SSCs |
ISTH SSC |
2020 |
|
WFH Guidelines for the Management of Hemophilia, 3rd edition |
WFH |
2020 |
|
Investigation and management of erythrocytosis |
|
2020 |
|
Guideline for the diagnosis and management of the rare coagulation disorders. A United Kingdom Haemophilia Centre Doctors’ Organization guideline on behalf of the British Committee for Standards in Haematology |
UKHCDO |
2014 |
|
Patient self-testing and self-management oforal anticoagulant with vitamin K antagonists: guidance from the British Committee for Standards in Haematology |
BCSH |
2014 |
|
Diagnosis and management of acquired coagulation inhibitors: a guideline form UKHCDO |
UKHCDO |
2013 |
|
Diagnosis and treatment of factor VIII and IX inhibitors in congenital haemophilia: (4th edition) |
UKHCDO |
2013 |
|
Review of the NICE guidelines for multiple myeloma |
NCBI |
2017 |
|
WFH Guidelines for the Management of Hemophilia, 2nd edition |
WFH |
2012 |
|
McMaster RARE-Bestpractices clinical practice guideline on diagnosis and management of the catastrophic antiphospholipid syndrome |
McMaster RARE-Bestpractices project group |
2018 |
|
European Myeloma Network recommendations on tools for the diagnosis and monitoring of multiple myeloma: what to use and when |
European Myeloma Network |
2018 |
|
EULAR recommendations for the management of antiphospholipid syndrome in adults |
EULAR |
2019 |
|
Guidelines on the use of therapeutic apheresis in clinical practice - Evidence-based approach from the Writing Committee of the American Society for Apheresis: The Eighth Special Edition |
American Society for Apheresis |
2019 |
|
Acquired hemophilia A: Updated review of evidence and treatment guidance. |
Hemostasis and Thrombosis Research Society of North America (HTRS) |
2017 |
|
Emergency management in patients with haemophilia A and inhibitors on prophylaxis with emicizumab: AICE practical guidance in collaboration with SIBioC, SIMEU, SIMEUP, SIPMeL and SISET |
AICE |
2020 |
|
ISTH Guidelines for Treatment of Thrombotic Thrombocytopenic Purpura |
ISTH |
2020 |
|
International Recommendations On The Diagnosis And Treatment Of Acquired Hemophilia A |
|
2020 |
|
Anticoagulant therapy for splanchnic vein thrombosis |
ISTH SSC |
2020 |
|
Use of direct oral anticoagulants in patients with thrombotic antiphospholipid syndrome: Guidance from the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis |
ISTH SSC |
2020 |
|
Second International Guidelines for the Diagnosis and Management of Hereditary Hemorrhagic Telangiectasia |
|
2020 |
|
Good practice statements (GPS) for the clinical care of patients with thrombotic thrombocytopenic purpura |
ISTH |
2020 |
|
American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism |
ASH |
2020 |
|
Canadian stroke best practice recommendations: Management of Spontaneous Intracerebral Hemorrhage, 7th Edition Update 2020 |
Canadian Stroke Best Practice Recommendations (CSBPR) |
2020 |
|
2020 ACC Expert Consensus Decision Pathway on Management of Bleeding in Patients on Oral Anticoagulants: A Report of the American College of Cardiology Solution Set Oversight Committee |
ACC |
2020 |
|
2021 Guidelines on the Diagnosis and Management of VWD |
ASH, ISTH, NHF, WFH |
2021 |
Management of hemostatic complications in acute leukemia: Guidance from the SSC of the ISTH |
ISTH SSC |
2020 |
Post-analytical |
|||
Recommendations on the Standardization of Critical Results in Hematology – Adult Population |
ICSH |
2016 |
|
Guideline Papers |
ICSH |
2018 |
|
Guideline Papers |
BSH |
2016 |
|
International Council for Standardization in Haematology Recommendations for Hemostasis Critical Values, Tests, and Reporting |
ICSH |
2020 |
|
Comprehensive review of the impact of direct oral anticoagulants on thrombophilia diagnostic tests: Practical recommendations for the laboratory |
|
2020 |
|
American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer |
ASH |
2021 |
|
Coagulopathy and Hematology Guidance related to COVID-19 Disclaimer: COVID-19 research and publications is rapidly evolving. ISLH will strive to have the most up-to-date resources available however there may be some delay in posting. |
|||
Remdesivir for severe covid-19: a clinical practice guideline |
BMJ Rapid Recommendation |
2020 |
|
IFCC Information Guide on COVID-19 |
IFCC |
2020 |
|
Thromboembolism and Anticoagulant Therapy During the COVID-19 Pandemic: Interim Clinical Guidance from the Anticoagulant Forum |
Anticoagulant Forum |
2020 |
|
ISTH interim guidance on recognition and management of coagulopathy in COVID- ADDENDUMS to above publication: ISTH interim guidance on recognition and management of coagulopathy in COVID-19: A Comment ISTH interim guidance to recognition and management of coagulopathy in COVID-19 Laboratory haemostasis monitoring in COVID-19 |
ISTH |
2020 |
|
Chinese expert consensus on diagnosis and treatment of coagulation dysfunction in COVID-19 |
Chinese Society on Thrombosis and Hemostasis |
2020 |
|
Practical guidance for the management of adults with Immune Thrombocytopenia during the COVID-19 pandemic |
Reviewed by UK ITP Forum |
2020 |
|
Scientific and Standardization Committee Communication: Clinical Guidance on the Diagnosis, Prevention and Treatment of Venous Thromboembolism in Hospitalized Patients with COVID-19 |
ISTH SSC |
2020 |
|
Prevention, diagnosis and treatment of venous thromboembolism in patients with COVID-19: CHEST Guideline and Expert Panel Report |
CHEST |
2020 |
|
The need for accurate D-dimer reporting in COVID-19: Communication from the ISTH SSC on Fibrinolysis |
ISTH SSC |
2020 |
|
COVID-19 and its implications for thrombosis and anticoagulation |
ASH |
2020 |
|
A Systematic Approach for Managing Venous Thromboembolism in Patients with COVID-19 - International Society on Thrombosis and Haemostasis, Inc. |
ISTH |
2020 |
|
Testing for SARS-CoV-2 (COVID-19): a systematic review and clinical guide to molecular and serological in-vitro diagnostic assays |
|
2020 |
Treatment of patients with nonsevere and severe coronavirus disease 2019: an evidence based guideline |
|
2020 |
Consensus-Based Clinical Recommendations and Research Priorities for Anticoagulant Thromboprophylaxis in Children Hospitalized for COVID-19 Related Illness |
ISTH SSC |
2020 |
Management of the thrombotic risk associated with COVID-19: Guidance for the hemostasis laboratory |
|
2020 |
ISTH DIC subcommittee communication on anticoagulation in COVID-19 |
ISTH SSC |
2020 |
Quality of early evidence on the pathogenesis, diagnosis, prognosis and treatment of COVID-19 |
|
2020 |
|
Venous Thromboembolism in COVID-19 |
|
2020 |
|
Anticoagulation in COVID-19: Effect of Enoxaparin, Heparin, and Apixaban on Mortality |
|
2020 |
|
The hematology laboratory’s response to the COVID-19 pandemic: A scoping review |
|
2020 |
Thromboembolism risk of COVID-19 is high and associated with a higher risk of mortality: A systematic review and meta-analysis |
|
2020 |
Routine laboratory testing to determine if a patient has COVID-19 |
Cochrane COVID-19 Diagnostic Test Accuracy Group |
2020 |
|
The Infectious Diseases Society of America Guidelines on the Diagnosis of COVID-19: Molecular Diagnostic Testing |
Infectious Diseases Society of America |
2021 |
|
ASH Guidelines on Use of Anticoagulation in Patients with COVID-19 |
ASH |
2021 |
|
The ADAMTS13-von Willebrand factor axis in COVID-19 patients |
|
2021 |
|
A living WHO guideline on drugs to prevent covid-19 |
WHO |
2021 |
|
Thrombosis Canada Statement on Astrazeneca COVID-19 Vaccine and Thrombosis |
Thrombosis Canada |
2021 |
|
ISTH Statement on Astrazeneca COVID-19 Vaccine and Thrombosis |
ISTH |
2021 |
|
THROMBOSIS CANADA UPDATED STATEMENT ON ASTRAZENECA VACCINE AND BLOOD CLOTS Thrombosis Canada seeks to reassure the public regarding blood clot risk and COVID-19 vaccines |
Thrombosis Canada |
2021 |
|
COVID-19 Vaccine AstraZeneca: benefits still outweigh the risks despite possible link to rare blood clots with low blood platelets |
European Medicines Agency (EMA) |
2021 |